142 related articles for article (PubMed ID: 34544970)
1. Clinical Efficacy of Intracoronary Papaverine After Nicorandil Administration for Safe and Optimal Fractional Flow Reserve Measurement.
Inoue K; Sonoda S; Naka Y; Okabe H; Setoyama K; Miura T; Anai R; Araki M; Kataoka M
Int Heart J; 2021 Sep; 62(5):962-969. PubMed ID: 34544970
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of maximal hyperemia by the incremental dose of intracoronary papaverine.
Nakayama M; Tanaka N; Yamashita J; Iwasaki K
Cardiovasc Interv Ther; 2020 Oct; 35(4):371-378. PubMed ID: 31939068
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.
Okabe Y; Otowa K; Mitamura Y; Murai H; Usui S; Kaneko S; Takamura M
Heart Vessels; 2018 Nov; 33(11):1358-1364. PubMed ID: 29713819
[TBL] [Abstract][Full Text] [Related]
4. Impact of additional intracoronary nicorandil administration during fractional flow reserve measurement with intravenous adenosine 5'-triphosphate infusion.
Takami H; Sonoda S; Muraoka Y; Sanuki Y; Kashiyama K; Fukuda S; Oginosawa Y; Tsuda Y; Araki M; Otsuji Y
J Cardiol; 2017 Jan; 69(1):119-124. PubMed ID: 26947100
[TBL] [Abstract][Full Text] [Related]
5. Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment.
Verdoia M; Erbetta R; Sagazio E; Barbieri L; Negro F; Suryapranata H; Kedhi E; De Luca G;
Int J Cardiol; 2019 Jun; 284():16-21. PubMed ID: 30293665
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements.
Kato D; Takashima H; Waseda K; Kurita A; Kuroda Y; Kosaka T; Kuhara Y; Ando H; Maeda K; Kumagai S; Sakurai S; Suzuki A; Toda Y; Watanabe A; Sato S; Fujimoto M; Mizuno T; Amano T
Heart Vessels; 2015 Jul; 30(4):477-83. PubMed ID: 24748047
[TBL] [Abstract][Full Text] [Related]
7. Estimation of coronary flow reserve by intracoronary administration of nicorandil: comparison with intracoronary administration of papaverine.
Inoue F; Hashimoto T; Fujimoto S; Uemura S; Kawamoto A; Dohi K
Heart Vessels; 1998; 13(5):229-36. PubMed ID: 10483772
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined administration of intracoronary papaverine plus intravenous adenosine 5'-triphosphate in assessment of fractional flow reserve.
Nishi T; Kitahara H; Iwata Y; Fujimoto Y; Nakayama T; Takahara M; Sugimoto K; Kobayashi Y
J Cardiol; 2016 Dec; 68(6):512-516. PubMed ID: 26811149
[TBL] [Abstract][Full Text] [Related]
9. Utility and Validity of Intracoronary Administration of Nicorandil Alone for the Measurement of Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis.
Ishibuchi K; Fujii K; Otsuji S; Takiuchi S; Hasegawa K; Tamaru H; Ishii R; Yasuda S; Nakabayashi S; Yamamoto W; Kusumoto H; Taniguchi Y; Kakishita M; Shimatani Y; Higashino Y
Circ J; 2019 Sep; 83(10):2010-2016. PubMed ID: 31413232
[TBL] [Abstract][Full Text] [Related]
10. Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.
Nishi T; Kitahara H; Fujimoto Y; Nakayama T; Nagashima K; Hanaoka H; Kobayashi Y
Heart Vessels; 2018 Dec; 33(12):1570-1575. PubMed ID: 29858919
[TBL] [Abstract][Full Text] [Related]
11. Effects of caffeine on fractional flow reserve values measured using intravenous adenosine triphosphate.
Nakayama M; Chikamori T; Uchiyama T; Kimura Y; Hijikata N; Ito R; Yuhara M; Sato H; Kobori Y; Yamashina A
Cardiovasc Interv Ther; 2018 Apr; 33(2):116-124. PubMed ID: 28110424
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility and safety of intracoronary nicorandil as a hyperemic agent for the measurement of fractional flow reserve.
Chhabria R; Mehta NP; Jain N; Handa SR; Mehta AB
Indian Heart J; 2020; 72(6):603-605. PubMed ID: 33357653
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary adenosine-induced ventricular arrhythmias during fractional flow reserve (FFR) measurement: case series and literature review.
Patel HR; Shah P; Bajaj S; Virk H; Bikkina M; Shamoon F
Cardiovasc Interv Ther; 2017 Oct; 32(4):374-380. PubMed ID: 27577946
[TBL] [Abstract][Full Text] [Related]
14. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.
Nakayama M; Tanaka N; Sakoda K; Hokama Y; Hoshino K; Kimura Y; Ogawa M; Yamashita J; Kobori Y; Uchiyama T; Aizawa Y; Yamashina A
Circ J; 2015; 79(3):530-6. PubMed ID: 25746536
[TBL] [Abstract][Full Text] [Related]
15. Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.
Goto M; Sato M; Kitazawa H; Takahashi M; Fuse K; Saito A; Okabe M; Aizawa Y
Intern Med; 2014; 53(15):1629-31. PubMed ID: 25088875
[TBL] [Abstract][Full Text] [Related]
16. Additive value of nicorandil on ATP for further inducing hyperemia in patients with an intermediate coronary artery stenosis.
Kobayashi Y; Okura H; Neishi Y; Higa T; Kobayashi Y; Uemura S; Yoshida K
Coron Artery Dis; 2017 Mar; 28(2):104-109. PubMed ID: 27611876
[TBL] [Abstract][Full Text] [Related]
17. Maximal hyperemia in the assessment of fractional flow reserve: intracoronary adenosine versus intracoronary sodium nitroprusside versus intravenous adenosine: the NASCI (Nitroprussiato versus Adenosina nelle Stenosi Coronariche Intermedie) study.
Leone AM; Porto I; De Caterina AR; Basile E; Aurelio A; Gardi A; Russo D; Laezza D; Niccoli G; Burzotta F; Trani C; Mazzari MA; Mongiardo R; Rebuzzi AG; Crea F
JACC Cardiovasc Interv; 2012 Apr; 5(4):402-8. PubMed ID: 22516396
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine.
Matsumoto H; Mikuri M; Masaki R; Tanaka H; Ogura K; Arai T; Sakai R; Oishi Y; Okada N; Shinke T
Int J Cardiol; 2020 Sep; 314():1-6. PubMed ID: 32387252
[TBL] [Abstract][Full Text] [Related]
19. Duration of Hyperemia With Intracoronary Administration of Papaverine.
Mizukami T; Sonck J; Gallinoro E; Kodeboina M; Canvedra A; Nagumo S; Bartunek J; Wyffels E; Vanderheyden M; Shinke T; De Bruyne B; Collet C
J Am Heart Assoc; 2021 Feb; 10(3):e018562. PubMed ID: 33459027
[No Abstract] [Full Text] [Related]
20. Sinus Standstill in a Patient after Intracoronary Papaverine Administration for a Coronary Fractional Flow Reserve.
Nauchi M; Sakai T; Yamawaki M; Ito Y
Int Heart J; 2018 May; 59(3):630-633. PubMed ID: 29681575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
